Have we improved in preventing and treating acute graft-versus-host disease? - Wikidata - awgldk - TriplyDB

Have we improved in preventing and treating acute graft-versus-host disease?

Have we improved in preventing and treating acute graft-versus-host disease?

http://www.wikidata.org/entity/Q36203692

about

Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.Inhibitory effects of merocyanine 540-mediated photodynamic therapy on cellular immune functions: A role in the prophylaxis of graft-versus-host disease?Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation.Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation.Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation.A novel differential predict model based on matrix-assisted laser ionization time-of-flight mass spectrometry and serum ferritin for acute graft-versus-host disease.Cellular immune function monitoring after allogeneic haematopoietic cell transplantation: evaluation of a new assay.The Safety of Non-Expanded Multipotential Stromal Cell Therapies

P2860

Q35760517-4F39B683-4304-43B9-85D4-969BF61341C9 Q36359613-8099DED8-5966-48F3-9A80-DF9132C8A0DA Q37079016-36BDB231-B09F-426D-887F-B4F6AF8EA40C Q39041077-B3CEC210-A57A-4D71-8407-B18DCECBC451 Q40053904-3242E396-0374-48D7-B8B0-3D7848D646DF Q41762442-8E64F660-098B-435B-B62C-085CA1C98BC4 Q44550369-C8E10056-2ADE-453C-A5CA-A5CEE9C43BB3 Q56837269-4B6DEED5-CC94-468C-AA75-D6E94355E3CD

P2860

Have we improved in preventing and treating acute graft-versus-host disease?

http://www.wikidata.org/entity/Q36203692

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Have we improved in preventing and treating acute graft-versus-host disease?

@ast

Have we improved in preventing and treating acute graft-versus-host disease?

@en

type

label

Have we improved in preventing and treating acute graft-versus-host disease?

@ast

Have we improved in preventing and treating acute graft-versus-host disease?

@en

prefLabel

Have we improved in preventing and treating acute graft-versus-host disease?

@ast

Have we improved in preventing and treating acute graft-versus-host disease?

@en

P1433

Q36203692-D5A511A1-6531-42BF-A1F7-3CD46260E9DC

P1476

Q36203692-0DE717EA-905A-42E1-BDAF-729B981D3E1B

P2093

Q36203692-1C633DC6-DDBA-4D58-B297-A34BA74164D6

Q36203692-AAF5D31C-C665-4871-A5C4-135A21DFDC75

Q36203692-CE28B22D-26B5-4177-B539-98CF1330CB09

P2860

Q36203692-0C6FC975-CB89-4C3E-8CFB-3E3A28D02259

Q36203692-1100F10F-AA67-44DA-8C94-19DBC2ECB9F4

Q36203692-137E38B5-B433-4E84-93E3-0642DF201792

Q36203692-25A41554-694C-4848-9CA6-6ED4049D2311

Q36203692-2684F335-C8F2-4374-9C66-EB2ECDE40643

Q36203692-276258E8-81D0-4773-9C6B-03CAEDA1F227

Q36203692-306D1466-EADA-4574-AEE6-EDC88AC0000F

Q36203692-3CCC33B4-61D5-49D8-A61D-6D71EB358BA9

Q36203692-3EA60F06-EEB0-459F-8783-6D5E221F5F26

Q36203692-46D27747-07BC-4840-896B-9A1962A9DB9F

P304

Q36203692-AD71C61E-49A6-42D9-A913-7CE942A96A32

P31

Q36203692-A3EF87A9-CC67-493D-97AD-297FAFC16CC2

P356

Q36203692-949DEFE7-C9D8-42FF-B91B-7A6F20CF9B49

P433

Q36203692-4E22BA0B-D07F-43DC-BAE0-B8CCD737B42C

P478

Q36203692-14EA1671-A328-41D2-915F-71D4519D8039

P577

Q36203692-91CDD58E-749B-44DE-A4D4-9F437A9B5B0C

P698

Q36203692-B6DE8437-A715-4B8B-B753-D0E48915FEB9

P932

Q36203692-71D18AD3-7BF6-438D-B7D9-0252FA6F41EA

P356

MOH.0B013E32834B6196

P1433

Current Opinion in Hematology

P1476

Have we improved in preventing and treating acute graft-versus-host disease?

@en

P2093

Claudio Anasetti

http://www.w3.org/2001/XMLSchema#string

Joseph Pidala

http://www.w3.org/2001/XMLSchema#string

Lia Perez

http://www.w3.org/2001/XMLSchema#string

P2860

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Prognostic value of response after upfront therapy for acute GVHD

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study

T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies

Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials networ

Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.

How I treat refractory acute GVHD.

Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation.

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.

P304

408-413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MOH.0B013E32834B6196

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21912253

http://www.w3.org/2001/XMLSchema#string

P932

3432261

http://www.w3.org/2001/XMLSchema#string